InsidersTradesSigma
NutriBand Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the NutriBand Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, NutriBand Inc. has recorded 6 insider filings. Market capitalisation: €41.2m. The latest transaction was reported on 8 March 2023 (Don). Among the most active insiders: MELNIK SERGUEI. All data is accessible without an account.
6
Insider Decl.
0
Thresholds
€21,387
3 ops.
Buy Volume
·
0 ops.
Sell Volume
38Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 25,131 of 26,212 companies
14.5
score / 100
Value9
Quality20
FCF yld-12%
Earn yld-73%
EV/EBITDA·
ROE-146%
Gross mgn28%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 March 2023
Declarations6 total
5,000 shares0Common Stock, par value $0.001 per shareSEC:0001213900-23-018365:0
10,000 shares@ US$3.80100.0% of flowCommon StockSEC:0001213900-22-037877:0
500 shares@ US$4.030.0031% mcap8.3% of flowCommon Stock, par value $0.001 per shareSEC:0001213900-22-009352:0
Ideal exit: 21 Nov 2022 (T+270)
500 shares@ US$4.030.0031% mcap8.3% of flowCommon Stock, par value $0.001 per shareSEC:0001213900-22-009240:0
Ideal exit: 21 Nov 2022 (T+270)
5,000 shares@ US$4.030.031% mcap83.3% of flowCommon Stock, par value $0.001 per shareSEC:0001213900-22-009192:0
Ideal exit: 21 Nov 2022 (T+270)
10,000 shares0Common Stock, par value $0.001 per shareSEC:0001213900-22-006347:0
6 of 6 declarations
About NutriBand Inc.
Nutriband Inc. is a U.S.-listed healthcare and pharmaceutical company traded on the NASDAQ in the United States. For investors, the company is best understood as a specialized transdermal drug-delivery developer with a strong focus on abuse-deterrent pharmaceutical technologies, especially in the context of the opioid crisis. Nutriband was incorporated in Nevada on January 4, 2016, and its operational headquarters are in Orlando, Florida. At this stage, the company is primarily a development-stage innovator rather than a broad commercial pharmaceutical platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1676047/000121390026049399/ea0287168-10k_nutriband.htm?utm_source=openai)) The core investment case centers on AVERSA™, Nutriband’s transdermal technology platform designed to improve the safety profile of skin-delivered medicines, particularly fentanyl-based patch products. The company also works on broader transdermal pharmaceutical development through its clinical subsidiary 4P Therapeutics. In addition, Nutriband says it has revenue-generating subsidiaries, including Pocono Pharmaceutical, which focuses on contract manufacturing, and Active Intelligence, which is associated with sports recovery products. This gives the group a mixed profile that combines R&D, contract services, and early-stage commercial activity. ([nutriband.com](https://www.nutriband.com/?utm_source=openai)) Competitively, Nutriband operates in a niche but potentially attractive segment of the pharmaceutical industry: higher-value transdermal systems where differentiation depends on intellectual property, clinical evidence, regulatory progress, and the ability to secure industrial partners. The company’s strategic positioning is tied to abuse-deterrent solutions, a theme that can resonate with investors looking at specialty pharma and drug-delivery innovation. That said, the risk profile remains elevated because monetization still depends heavily on clinical, regulatory, and commercial execution. ([nasdaq.com](https://www.nasdaq.com/press-release/nutriband-unveils-groundbreaking-innovation-in-transdermal-medications-2023-09-20-0?utm_source=openai)) Recent developments reinforce the company’s pipeline-driven profile. In 2025, Nutriband said it received final meeting minutes from a U.S. FDA meeting regarding AVERSA™ FENTANYL, with the aim of supporting an IND submission for a Human Abuse Potential clinical study. Earlier disclosures also highlighted the issuance of a U.S. patent for AVERSA™ Technology and referenced commercial projections for its lead product. From an equity research perspective, Nutriband remains a NASDAQ-listed U.S. micro-cap story with identifiable regulatory catalysts, but limited visibility until more clinical and commercial milestones are achieved. ([nasdaq.com](https://www.nasdaq.com/press-release/nutriband-announces-successful-meeting-completed-united-states-fda-its-abuse?utm_source=openai))
